Zeposia

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports
BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports
PR Newswire
Bristol Myers Squibb
AbbVie
Zeposia
Skyrizi
ulcerative colitis
Crohn's Disease
gastroentrologists
Flag link:
The first big test of Pfizer’s Arena buyout clears a PhIII in bid to catch up to Zeposia
The first big test of Pfizer’s Arena buyout clears a PhIII in bid to catch up to Zeposia
Endpoints
Pfizer
Zeposia
Bristol Myers Squibb
Arena Pharmaceuticals
etrasimod
Flag link:
Bristol Myers Squibb Just Got Some Great Regulatory News
Bristol Myers Squibb Just Got Some Great Regulatory News
Motley Fool
Bristol Myers Squibb
Zeposia
Europe
ulcerative colitis
Flag link:
Ventyx nabs a $152M upsized IPO to challenge BMS' Zeposia—and a backer with intimate knowledge of its rival
Ventyx nabs a $152M upsized IPO to challenge BMS' Zeposia—and a backer with intimate knowledge of its rival
Fierce Biotech
Ventyx Biosciences
IPOs
autoimmune disease
Bristol Myers Squibb
Zeposia
Flag link:
How Big Is Bristol Myers Squibb's Latest FDA Approval?
How Big Is Bristol Myers Squibb's Latest FDA Approval?
Motley Fool
Bristol Myers Squibb
Zeposia
ulcerative colitis
FDA
Flag link:
BMS Flying High in May With Opdivo, Zeposia FDA Approvals
BMS Flying High in May With Opdivo, Zeposia FDA Approvals
BioSpace
Bristol Myers Squibb
FDA
clinical trials
Opdivo
Zeposia
ozanimod
ulcerative colitis
Flag link:
Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches
Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches
Fierce Pharma
Bristol-Myers Squibb
generics
Revlimid
Zeposia
Reblozyl
Onureg
Flag link:
Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug
Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug
Endpoints
Bristol-Myers Squibb
Celgene
FDA
ulcerative colitis
priority review
Zeposia
Flag link:
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Fierce Pharma
Celgene
Bristol-Myers Squibb
Zeposia
Reblozyl
Onureg
Flag link:
Bristol Myers Squibb's Zeposia boosts remission rates over placebo in ulcerative colitis patients
Bristol Myers Squibb's Zeposia boosts remission rates over placebo in ulcerative colitis patients
Fierce Pharma
Bristol-Myers Squibb
Zeposia
ulcerative colitis
clinical trials
Flag link:
BMS' Recently Approved MS Drug Shows Promise in Ulcerative Colitis Study
BMS' Recently Approved MS Drug Shows Promise in Ulcerative Colitis Study
BioSpace
Bristol-Myers Squibb
Zeposia
ozanimod
ulcerative colitis
Flag link:
Bristol Myers Squibb's Zeposia launches into crowded MS market
Bristol Myers Squibb's Zeposia launches into crowded MS market
Fierce Pharma
Bristol-Myers Squibb
Celgene
Zeposia
drug launches
MS
multiple sclerosis
Flag link:
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia
Flag link: